Assembly Bio reports positive Phase 1a data for ABI-4334; to partner core inhibitor portfolio, focus on ABI-5366

ASSEMBLY BIOSCIENCES, INC.

ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.
Phase 1a safety: mild-to-moderate AEs, no pattern, no clinically significant ECG abnormalities.
Company will partner core inhibitor portfolio; no further internal clinical development for HBV cure.
Prioritizing ABI-5366 (genital herpes) with Phase 1 expected H1 2024; second candidate by end of 2024.
Cash runway extended into Q3 2024 due to reprioritization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.